FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis [1]

European Journal of Clinical Investigation

Volumn 37, Issue 2, 2007, Pages 153-154

  Valent, P ^a   Akin, C ^b,d   Metcalfe, D D ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIP1L1 PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR FUSION PROTEIN; HYBRID PROTEIN; IMATINIB; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ASSOCIATED HEMATOLOGICAL NONMAST CELL DISORDER; CANCER GRADING; CHRONIC EOSINOPHILIC LEUKEMIA; CONSENSUS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG INDICATION; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; HEMATOLOGIC DISEASE; LETTER; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MUTATION; PRIORITY JOURNAL; SYMPTOMATOLOGY; SYSTEMIC MASTOCYTOSIS; WORLD HEALTH ORGANIZATION;

HUMANS; HYPEREOSINOPHILIC SYNDROME; MASTOCYTOSIS, SYSTEMIC; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 33846099538     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01757.x     Document Type: Letter

References (11)

1. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukemia and hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001, pp. 29-31.
2. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879-91.
3. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6.
4. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988;62:965-72.
5. Horny H-P, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990;76:186-93.
6. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S-4S.
7. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-4.
8. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000;53:188-93.
9. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
10. Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM et al. Mastocytosis (Mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001, pp. 291-302.
11. Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 2004;34(S2):41-52.